Ophthalmology company Nicox SA (Euronext Growth Paris:ALCOX) announced on Tuesday that it has completed the generation and analysis of all clinical trial and long-term stability data required to support New Drug Application (NDA) submissions for NCX 470 in the United States and China.
The data package, compliant with International Council for Harmonisation guidelines, covers both drug substance and finished drug product and supports manufacturing, shelf-life and drug metabolism requirements.
The company is preparing for a pre-NDA meeting with the US Food and Drug Administration (FDA), with the US NDA submission on track for the first half of 2026 and the China submission expected shortly thereafter. Preparation of the NDA is being funded by licensing partner Kowa.
Nicox confirmed that the Phase 3 clinical program for NCX 470 in Japan was initiated in summer 2025 and is managed and financed by Kowa.
Physiomics secures follow-on UK contract for Phase 2 study support
Ascletis reports positive US Phase I data for oral IL-17 inhibitor ASC50
Dimerix completes adult recruitment in ACTION3 Phase 3 DMX-200 trial
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
Vanda files FDA Biologics License Application for imsidolimab in generalized pustular psoriasis
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion
Innovent Biologics' mazdutide injection meets Phase 1b clinical study primary endpoint
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
OTR Therapeutics agrees strategic collaboration and licence agreement with Zealand Pharma A/S
Privo Technologies doses first patient in first-in-human clinical trial of PRV131